Company* (Country; Symbol) |
Funding Institution |
Amount (US$M) |
Type |
Details (Date) |
Accentia Biopharmaceuticals Inc. (ABPI), Mayo Medical and Graduate Schools and the Virginia Bioinformatics Institute |
National Institutes of Health |
$2.4 |
Grant |
To support identification of which antigens of the Alternaria fungus are responsible for the inflammation of chronic sinusitis (6/1) |
ActoGeniX NV* (Belgium) |
Flanders government |
€3.07 |
Institute for Promotion of Innovation by Science and Technology in Flanders grant |
To support the discovery and development of programs based on TopAct, a platform for targeted delivery of biopharmaceuticals (7/12) |
AlphaRx Inc. (OTC BB:ALRX) |
U.S. Civilian Research and Development Foundation |
ND |
Grant |
To develop tuberculosis treatments based on colloidal lipid nanoparticles (6/12) |
AlphaVax Inc.* |
National Institute of Allergy and Infectious |
$3.6 |
Grant |
For advanced preclinical studies and manufacturing process development for adjuvant technologies based on the company's vector platform (7/10) |
Amarillo Biosciences Inc. (OTC BB:AMAR) |
Texas Tech University Health Services Center's School of Medicine |
ND |
Grant |
For a study on oral interferon therapy for chronic cough in patients with chronic obstructive pulmonary disease (6/15) |
Arcxis Biotechnologies* |
Department of Homeland Security |
$1 |
Phase II award |
To continue developing its BioPhalanx Analyzer, a portable instrument designed to rapidly detect biothreats in the field (7/17) |
Avexa (Australia; ASX:AVX) |
Australian government |
A$4.3 |
Grant |
To develop a new generation of HIV antiviral drugs using fragment-based drug design (5/30) |
Biocortech* (France) |
Paris Biocluster Pole de competitivite Medicen |
$1.9 |
Grant |
To discover treatments of psychiatric disorders (5/21) |
BioSystems International* (France) |
European Commission |
€2.9 |
Grant |
For the European Colon and Breast Cancer Diagnostics consortium, which is due to deliver within three years a panel of biomarkers/candidate diagnostics (6/20)** |
Bolder BioTechnology Inc.* |
NIH's National Institute of Allergy and Infectious Diseases |
$0.76 |
Phase II SBIR grant |
For preclinical studies and manufacturing optimization with the company's second-generation gamma interferon (7/16) |
BrainStorm Cell Therapeutics Inc. (OTC BB:BCLI) |
Israel's Chief Scientist Office |
$0.5 |
Grant |
For its work on Parkinson's disease using adult stem cells (7/19) |
Crucell NV (the Netherlands; CRXL) |
European Commission |
E1.7 |
Grant |
The grant was awarded to a consortium of nine universities and companies working in the field of influenza research; the funds will support preclinical and clinical testing of H5N1 vaccines (4/5) |
Cyntellect Inc.* |
National Institutes of Health |
$1.3 |
Phase II SBIR grant |
For continued new-application development on its laser-based LEAP system (5/9) |
EpiVax Inc.* |
National Heart, Lung and Blood Institute |
$0.528 |
SBIR grant |
For studies to provide proof-of-principle on a program to reengineer Factor VIII, which is used to control bleeding in hemophilia (6/27) |
Expression Genetics Inc.* |
FDA |
$1.05 |
Three-year grant |
To assist in the clinical development of EGEN-001 to treat advanced recurrent ovarian cancer (5/2) |
FASgen Inc.* |
National Cancer Institute |
ND |
SBIR grant |
For refinement of its serum FAS (fatty acid synthase) ELISA cancer diagnostic test, FAS-Detect ELISA (4/9) |
Fluxion Biosciences Inc.* |
National Institutes of Health |
$1.2 |
Phase II SBIR grant |
For the development of a multiplexed single-cell electroporation system (5/18) |
GeneGo Inc.* |
National Institute of Environmental Health Sciences |
$0.75 |
Phase II SBIR grant |
To develop functional descriptions for gene expression response to drugs and toxins as part of their MetaTox product line (5/15) |
Gene Network Sciences* and Cornell University |
Department of the Army |
ND |
Grant |
To build a computational model of Dehalococcoides, a type of bacteria used to dechlorinate toxic pollutants (5/16) |
IGI Inc. (AMEX:IG) |
National Cancer Institute |
ND |
STTR grant |
To evaluate a parathyroid hormone PTH (7-34) analogue to treat alopecia induced by chemotherapy in breast cancer patients (5/7) |
Immunotope Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
Grant |
To study the human immune response to Dengue virus infection as the basis for development of a vaccine against the pathogen (6/14) |
KineMed Inc.* |
Daiichi Sankyo Inc. (Japan) |
ND |
Grant |
To study the activity of colesevelam HCl, a bile acid sequestrant, in patients with Type II diabetes (5/21) |
Millenia Hope Inc. (FSE:MLF), University of Pittsburgh and Rutgers University |
National Institutes of Health |
$4.6 |
Grant |
The consortium will receive more than $4.6M over five years for a project on HIV RNase H natural product inhibitors (4/19) |
Mirus Bio Corp.* |
National Institute of General Medical Sciences |
$0.9 |
Phase II SBIR grant |
Funds will be used to optimize and extend its microRNA labeling technology for research and diagnostic applications (4/24) |
NanoBio Corp.* |
State of Michigan's 21st Century Job Fund |
$2.4 |
Grant |
To develop the company's drug candidate for the topical treatment of onychomycosis (7/11) |
Neuro-Hitech Inc. (NHPI) |
American Health Assistance Foundation |
$1 |
Grant |
A member of Neuro-Hitech's scientific advisory board received the grant to fund further research into compounds licensed to the company and targeted to treat Alzheimer's disease (6/5) |
Oligomerix Inc.* |
National Institute on Aging |
$0.234 |
SBIR Phase I grant |
To develop high-throughput technology for drug discovery in Alzheimer's disease (5/2) |
OncoMethylome Sciences SA (Belgium; BR:ONCOB) |
Walloon government |
E1.95 |
BioWin Marshall Plan grant |
The four-year research project involves a collaboration between OncoMethylome, the University of Liege and GlaxoSmithKline Biologicals, a unit of GSK plc in London, focused on early detection of women's cancers and on cancer vaccines; the total grant was E3.5M, of which the remainder went to the university (4/27) |
Oragenics Inc. (AMEX:ONI) |
National Cancer Institute |
ND |
SBIR grant |
To support a joint effort by scientists at Oragenics and the Lankenau Institute of Medical Research to identify biomarkers of colorectal cancer in early, middle and late stages of the disease (4/3) |
Plureon Corp.* |
National Institute of Diabetes & Digestive & Kidney Diseases |
$1 |
STTR grant |
Plureon will receive $1M over two years to advance its platform stem cell technology in diabetes; the grant could be extended for a total up to $4M (3/26) |
Pluristem Life Systems Inc. (OTC BB:PLRS) |
Israel's Chief Scientist Office |
$0.83 |
Research and development grant |
To support ongoing development of PLX, cells designed to be multipotent with the ability to differentiate into a variety of cell types (5/31) |
Pharmos Corp. (PARS) |
Office of the Chief Scientist of Israel's Ministry of Industry and Trade |
$1.5 |
Grant |
Pharmos was awarded the grant for development of drug candidates from the company's CB2-selective synthetic cannabinoid platform (3/29) |
Polyplus-transfection SA* (France) |
Association Francaise contre les Myopathies |
E0.08 |
Grant |
To finance the cGMP-compliant production process of its in vivo-jetPEI reagent to enables its use in gene therapy (5/14) |
Profectus BioSciences Inc.* |
Division of AIDS, National Institutes of Health |
$0.3 |
Phase I SBIR grant |
To develop enhanced adjuvants based on Profectus' technology (6/19) |
Profectus BioSciences Inc.* |
National Institute of Allergy and Infectious Diseases |
$0.2 |
Phase I SBIR grant |
To develop more effective anti-HIV antibodies based on the company's Antiviral Immune Modulation therapy technology (7/19) |
Protein Discovery Inc.* |
National Institutes of Health's National Center for Research Resources |
$0.75 |
Phase II SBIR grant |
For commercial development of MALDIplex M5 Sample Prep Station (4/26) |
Proximagen Neuroscience plc (UK; LSE:PRX) |
Michael J. Fox Foundation |
ND |
Grant |
To pursue research into its gene therapy approach for treating Parkinson's disease (7/25)** |
PTC Therapeutics Inc.* |
National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases |
$15.4 |
Five-year grant |
For further research into Duchenne muscular dystrophy, supporting preclinical research by PTC and the University of Pennsylvania School of Medicine (7/10) |
Samaritan Pharmaceuticals Inc. (AMEX:LIV) |
National Institute of Mental Health |
$0.25 |
STTR grant |
For continued development of compounds in the areas of viral replication suppression and neuronal protection (6/7) |
TriLink BioTechnologies* |
National Institutes of Health |
$0.1 |
Phase I SBIR grant |
To investigate a new approach for Hot Start activation in PCR (5/15) |
VASTox plc (UK; LSE:VOX) |
Welsh Development Agency |
£0.4 |
SMARTCymru program grant |
To support the research and development work undertaken at VASTox's Aberystwyth facility (6/20) |
Vical Inc. (VICL) |
National Institute of Allergy and Infectious Diseases |
$6 |
Grant |
To develop a DNA vaccine manufacturing process (6/12) |
Zen-Bio Inc.* |
National Institutes of Health |
$0.185 |
Phase I SBIR grant |
To fund the isolation and culturing of skeletal muscle cells (6/12) |
Notes: | ||||
* Indicates a privately held company; ** Denotes the date the item ran in BioWorld International. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; BR = Brussels Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | ||||
